Business Context and Reporting Period
This Form 8-K is filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on August 16, 2016. The report discloses an unregistered sale of equity securities pursuant to Item 3.02.
Key Financial Metrics
The filing details a specific capital raise transaction rather than periodic financial performance metrics.
- Transaction Value: $5,000,000
- Shares Issued: 2,616,431 shares of common stock
- Purchase Price: $1.911 per share (based on the 10-day VWAP from August 1 to August 12, 2016)
- Purchaser: Helsinn Investment Fund SA
- Regulatory Status: Exempt from registration under Section 4(a)(2) of the Securities Act of 1933
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the issuance of 2,616,431 shares of common stock to Helsinn Investment Fund SA, resulting in a capital infusion of $5,000,000. This transaction was executed under a Common Stock Purchase Agreement dated August 5, 2016.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, or specific risk factors beyond the standard disclosure of the unregistered sale.
Investor Verification Checklist
- Verify the exact number of shares issued (2,616,431) and the calculation based on the $1.911 VWAP.
- Confirm the identity of the purchaser (Helsinn Investment Fund SA) and any related party status.
- Review the August 9, 2016 Form 8-K referenced in the text for the full terms of the Equity Agreement.
- Check subsequent filings for the impact of this issuance on total outstanding shares and dilution.